Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMICUS THERAPEUTICS, INC. Director's Dealing 2017

Jan 5, 2017

31523_dirs_2017-01-05_df593dac-2c3a-4f65-96fa-c35ce568f58c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2017-01-03

Reporting Person: Campbell Bradley L (Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-01-03 Common Stock A 74525 $0.00 Acquired 127475 Direct
2017-01-03 Common Stock M 100000 Acquired 227475 Direct
2017-01-03 Common Stock F 50950 $5.13 Disposed 176525 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-01-03 Stock Options (right to buy) $5.13 A 103578 Acquired 2027-01-03 Common Stock (103578) Direct
2017-01-03 Restricted Stock Units $ M 100000 Disposed Common Stock (100000) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2018. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2018, with the final installment vesting on January 1, 2021.

F3: On June 26, 2014, the reporting person was granted 100,000 restricted stock units, vesting in full on July 1, 2016.